Publication

Indications to teriparatide treatment in patients with osteoporosis

Journal Paper/Review - Nov 7, 2011

Units
PubMed
Doi

Citation
Rizzoli R, Kraenzlin M, Krieg M, Mellinghoff H, Lamy O, Lippuner K. Indications to teriparatide treatment in patients with osteoporosis. Swiss Med Wkly 2011; 141:w13297.
Type
Journal Paper/Review (English)
Journal
Swiss Med Wkly 2011; 141
Publication Date
Nov 7, 2011
Issn Electronic
1424-3997
Pages
w13297
Brief description/objective

To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.